Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
We are excited to further demonstrate the potential of 1104 to change disease management and treatment experience for the diversity of patients living with allergic diseases.
- We are excited to further demonstrate the potential of 1104 to change disease management and treatment experience for the diversity of patients living with allergic diseases.
- Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies.
- 1104 is a peptide derived from a natural immune-regulatory protein and is entering Phase 2 clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease.
- The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.